Esomeprazole Magnesium for Delayed-Release Oral Suspension, 40 mg, 30-count Single-Dose Packets p...

FDA Drug Recall #D-0442-2025 — Class II — May 13, 2025

Recall Summary

Recall Number D-0442-2025
Classification Class II — Moderate risk
Date Initiated May 13, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Zydus Pharmaceuticals (USA) Inc
Location Pennington, NJ
Product Type Drugs
Quantity 30,674 30 sachets/carton

Product Description

Esomeprazole Magnesium for Delayed-Release Oral Suspension, 40 mg, 30-count Single-Dose Packets per carton, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-849-94

Reason for Recall

Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing during long term stability.

Distribution Pattern

Nationwide -in the USA

Lot / Code Information

Lot # M311638, Exp 07/2025, M400374, Exp 10/2025, M402496, Exp 02/2026, M407998, Exp 05/2026, M502247, Exp 11/2026, M414770, M414512, Exp 09/2026.

Other Recalls from Zydus Pharmaceuticals (USA) Inc

Recall # Classification Product Date
D-0400-2026 Class II Icosapent Ethyl Capsules, 1 gram, 120 Capsules ... Mar 9, 2026
D-0295-2026 Class II Icosapent Ethyl capsules, 1 gram, 120-count bot... Dec 30, 2025
D-0247-2026 Class III traZODONE Hydrochloride Tablets, USP, 100mg, 1,... Dec 19, 2025
D-0159-2026 Class II Bromocriptine Mesylate Capsules, USP, 5 mg, 30 ... Oct 23, 2025
D-0152-2026 Class II clomiPRAMINE Hydrochloride, Capsules, USP, 25 m... Oct 22, 2025

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.